High Content Screening Trends
Friday, September 02, 2005
Highlights of this Report:
The main survey looked at the extent to which HCS instruments have been deployed; interest to acquire new HCS systems; which research groups are planning to use HCS; where and for which applications HCS is currently being applied in drug discovery; instrumentation preferences for HCS; live-cell imaging requirements; HCS informatics; future trends, limitations and unmet needs in HCS. In addition, a survey supplement documents user perceptions of HCS instrument manufacturers and HCS purchasing preferences/decision factors.
The main survey collected 75 responses (66 complete and 9 partially filled out) from 42 different Pharma/Biotech/CRO companies and 20 University/Research Institutes. The survey supplement collected 47 responses from 32 different Pharma/Biotech/CRO companies and 10 University/Research Institutes.
Responses from Pharma/Biotech/CRO were split geographically 57% North America and 43% Europe. Responses from University/Research Institutes were split geographically 95% North America and 5% Europe.
Survey respondents were either existing users of HCS systems or persons interested in applying HCS/purchasing HCS systems, and were drawn from 23 Large Pharma, 29 Small Pharma/Biotechs, 2 CROs and 20 University/Research Institute Labs. The job role/position of the majority of survey respondents was either Senior Scientist, Principal Investigator or Director.
Survey respondents represented 30 assay development and primary screening (HTS) labs, 6 therapeutic area labs, 5 secondary screening labs, 3 hits-to-leads (lead optimization) labs, 4 compound profiling labs, 2 leads-to-candidate labs, 4 other Pharma and Biotech lab functions and 21 University or Research labs.
Survey results were expressed as an average of all survey respondents. In addition, the data was fully reanalyzed after sub-division into the following survey groups: 1) Large Pharma; 2) Small Pharma/Biotech; 3) University/Research Institutes; 4) HCS Users; and 5) HCS Non-Users.
51 HCS user labs (40 Pharma/Biotech/CR0 and 11 University/Research Institutes) responded to the survey and a total of 72 HCS instrument purchases (up to the end of 2004) were identified (53 units in Pharma/Biotech/CR0 and 19 units in University/Research Institutes). Cellomics ArrayScan® HCS reader was the most common instrument purchased.
40 labs, many new to HCS (representing 31 Pharma/Biotech/CR0 and 9 University/Research Institutes) indicated they had budgeted or had plans to acquire an HCS instrument over the coming 3 years (2005 to 2007). Interest in the different HCS system brands was documented.
A model predicting the growth of instrument sales to the Pharma Market was developed. The model predicts sales of around 50 HCS systems/year in 2005 and 2006.
The breakdown of the HCS users operating budgets (excluding Capex purchases) was analyzed with bulk reagents (fluorescent probes and antibodies) representing the largest single item purchased.
On average labs involved in HCS plan 6.1 different HCS assays in 2005, with greatest interest from Oncology and Neurobiology research groups.